C4 Therapeutics (CCCC)
(Delayed Data from NSDQ)
$3.16 USD
-0.16 (-4.82%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $3.23 +0.07 (2.22%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CCCC 3.16 -0.16(-4.82%)
Will CCCC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CCCC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CCCC
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates
CCCC: What are Zacks experts saying now?
Zacks Private Portfolio Services
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates
C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for CCCC
Golden Cross appears for CCCC after 1.78% move
Upper Bollinger Band Walk appears for CCCC after 0.88% move
CCCC forms Jack-in-the-box Bullish on September 16
Analyst Barclays Initiates Coverage on C4 Therapeutics (CCCC) with Overweight Rating | CCCC ...
Oncology Investment Surge Hits $1.3B as Private Sector Fills Public Funding Gaps